Simon Sturge Biography and Net Worth

Director of MoonLake Immunotherapeutics

Simon Sturge, is a Director of MoonLake and serves as Chairman of the board of directors. Prior to MoonLake, Mr. Sturge was the Chief Executive Officer of Kymab Ltd, a biotechnology company, from 2019 to 2021. Prior to that, Mr. Sturge was at Merck KGaA, from 2013 to 2019, most recently as the Chief Operating Officer. He was Senior Vice President at Boehringer Ingelheim, from 2010 to 2013. In addition, Mr. Sturge is also a director at two private biotechnology companies, a private consulting company, and a private investment company. Mr. Sturge was also a director at Feedback PLC, a publicly-traded biotechnology company listed on the London Stock Exchange, from 2017 to 2021.

What is Simon Sturge's net worth?: The estimated net worth of Simon Sturge is at least $9.07 million as of October 4th, 2024. Mr. Sturge owns 171,980 shares of MoonLake Immunotherapeutics stock worth more than $9,068,505 as of December 3rd. This net worth approximation does not reflect any other investments that Mr. Sturge may own. Learn More about Simon Sturge's net worth.
How do I contact Simon Sturge?: The corporate mailing address for Mr. Sturge and other MoonLake Immunotherapeutics executives is , , . MoonLake Immunotherapeutics can also be reached via phone at 41-41-510-8022 and via email at [email protected]. Learn More on Simon Sturge's contact information.
Has Simon Sturge been buying or selling shares of MoonLake Immunotherapeutics?: In the last ninety days, Simon Sturge has sold $9,186,120.00 in shares of MoonLake Immunotherapeutics stock. Most recently, Simon Sturge sold 171,000 shares of the business's stock in a transaction on Friday, October 4th. The shares were sold at an average price of $53.72, for a transaction totalling $9,186,120.00. Following the completion of the sale, the director now directly owns 171,980 shares of the company's stock, valued at $9,238,765.60. Learn More on Simon Sturge's trading history.
Who are MoonLake Immunotherapeutics' active insiders?: MoonLake Immunotherapeutics' insider roster includes Matthias Bodenstedt (CFO), and Simon Sturge (Director). Learn More on MoonLake Immunotherapeutics' active insiders.
Are insiders buying or selling shares of MoonLake Immunotherapeutics?: In the last twelve months, insiders at the sold shares 10 times. They sold a total of 432,717 shares worth more than $24,287,059.52. The most recent insider tranaction occured on October, 4th when Director Simon Sturge sold 171,000 shares worth more than $9,186,120.00. Insiders at MoonLake Immunotherapeutics own 12.0% of the company. Learn More about insider trades at MoonLake Immunotherapeutics.
Information on this page was last updated on 10/4/2024.

Simon Sturge Insider Trading History at MoonLake Immunotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/4/2024	Sell	171,000	$53.72	$9,186,120.00	171,980

Simon Sturge Buying and Selling Activity at MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Company Overview

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Today's Range

Now: $52.73

$52.73

$56.00

50 Day Range

MA: $50.27

$46.20

$55.47

2 Week Range

Now: $52.73

$37.55

$64.98

Volume

76,002 shs

Average Volume

364,621 shs

Market Capitalization

$3.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Media Is Mocking Elon, But Wait Until They See This Demo

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.